Recruiting

Melatonin

Sponsor:

Natalie Denburg

Code:

NCT03954899

Conditions

Mild Cognitive Impairment

Cognitive Decline

Healthy Aging

Eligibility Criteria

Sex: All

Age: 56 - 70+

Healthy Volunteers: Accepted

Interventions

melatonin

placebo

Study Details

Brief summary:

The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-). AD biomarkers will be measured from cerebrospinal fluid (CSF) obtained from lumbar punctures. Cognitive function will be evaluated with routine neuropsychological tests.

AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.

Conditions

Mild Cognitive Impairment

Cognitive Decline

Healthy Aging

Study ID

NCT03954899

Start date

Nov 12, 2019

Status verified date

Feb, 2025

Completion date

Nov, 2025

Anticipated

Primary completion date

Nov, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 56 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. between ages of 56-85 years
2. all participants must score 18 or above on Montreal Cognitive Assessment (MoCA);
3. all participants must have a clinical dementia rating (CDR) Sum of boxes <1;
4. need to be willing to undergo CSF LP on two occasions over the course of their participation,
5. need to be able and willing to stop using any prescription or non-prescription sleep aids (e.g.(e.g. Ambien, Sonata, Lunesta, Belsomra, Rozerem, Halcion, Intermezzo, Doxepin, Melatonin, etc.) for the duration of the study except for study-issued medications
6. BMI < 35 at the time of enrollment
7. willing to bring a study partner (spouse, child or friend) who knows them well to each of the four visits

AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.

The exclusion criteria are:

1. Individuals with any of the following conditions/ diseases will be excluded:

Obstructive sleep apnea (OSA) without CPAP use, chronic obstructive pulmonary disease, emphysema, major psychiatric disease (bipolar, schizophrenia), history of alcohol/drug abuse, neurodegenerative disease diagnosis (e.g. Parkinson's, Lewy body, ALS, MS), prior history of stroke or traumatic brain injury, have undergone chemotherapy in the past 2 years, have been hospitalized for injury/surgery in the past three-months.
2. CDR>=1, clinically significant depression/anxiety (GDS>=9; GAI>=9 ),
3. Participants who are on any of the following medications will be excluded: Fluvoxamine (Luvox)/ Fluoxetine (Prozac), Nifedipine (a blood pressure medication), all anti-coagulants (e.g. Warfarin, Coumadin, Heparin, , Lovenox, Xarelto, Pradaxa, etc.), anti-seizure drugs (e.g. Acetazolamide, Carbamazepine, Clobazam, Clonazepam, Gabapentin, etc.), muscle relaxants (e.g.Baclofen, Valium/ diazepam, Flexeril, etc.), or narcotic pain relievers (e.g.Codeine, Tramadol, Hydrocodone, Demerol, etc).

Study Design

Enrollment

230 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: MCI+ Melatonin 5mg

MCI+ individuals receiving 5mg of melatonin-OTC for a period of 9 months

placebo comparator: MCI+ placebo

MCI+ individuals receiving placebo for a period of 9 months

experimental: MCI- Melatonin 5mg

MCI- individuals receiving 5mg of melatonin-OTC for a period of 9 months

placebo comparator: MCI- placebo

MCI- individuals receiving placebo for a period of 9 months

Interventions

melatonin

5mg of melatonin-otc 30 minutes before sleep

placebo

placebo 30 minutes before sleep

Primary outcome measure

  • Episodic memory [ Time Frame: Assessed at pre-treatment (week-8), and two post-treatment occasions: week-16 and week-44. ]

Central Contacts and Locations

Central contacts

Locations

University of Iowa Hospitals & Clinics

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

Principal Investigator:

Natalie Denburg, Ph.D.

More Information

Sponsor

Natalie Denburg

Last update posted

Mar 4, 2025

Last verified

Feb, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Natalie Denburg on 2025-03-04.